FDA Drug Approval: A Black and White Issue?

DSpace/Manakin Repository

FDA Drug Approval: A Black and White Issue?

Show simple item record

dc.contributor.advisor Hutt, Peter Barton en_US
dc.contributor.author Yonker, Stephanie A. en_US
dc.date.accessioned 2012-06-07T20:42:48Z
dc.date.issued 2006 en_US
dc.identifier.citation FDA Drug Approval: A Black and White Issue? (2006 Third Year Paper) en
dc.identifier.uri http://nrs.harvard.edu/urn-3:HUL.InstRepos:8852196
dc.description.abstract The FDA should judiciously limit the FDA approval of race-specific drugs to situations in which the utilization of racial categories is based on statistically significant scientific data and necessity and, in such cases, the meaning of race utilized should be defined. The term “race†is an inherently ambiguous social construct making the FDA approval of race-specific drugs and use of race in FDA approval decisions dangerous with debatable scientific legitimacy. Further, race is generally used in drug trials as a crude proxy for the determination of genetic variation, which tends to be both over and under-inclusive in determining the efficacy or safety of a drug for any individual. The limited genetic validity of race is confounded by the reality that many population differences between races may be the result of socio-economic and environmental factors that are not per se innate or inherent to any racial population. While the scientific validity of race as biologically significant classification is debatable, the general public is likely to interpret the governmental approval of the drug by the FDA as evidence of inherent genetic differences between racial groups that will serve to only further racial discrimination and eugenic ideologies. Thus, the FDA should proceed cautiously by narrowly tailoring the use of race in the FDA approval of new drugs and require a showing of statistically significant scientific data and the need to rely on race because of the lack of genetic markers. en
dc.language.iso en_US en
dash.license LAA en_US
dc.subject Food and Drug Law en
dc.subject race-specific drug en
dc.title FDA Drug Approval: A Black and White Issue? en
dc.type Paper (for course/seminar/workshop) en_US
dc.date.available 2012-06-07T20:42:48Z

Files in this item

Files Size Format View
Yonker06.pdf 284.8Kb PDF View/Open
Yonker06.rtf 231.0Kb RTF file View/Open
Yonker06.html 137.4Kb HTML View/Open

This item appears in the following Collection(s)

Show simple item record

 
 

Search DASH


Advanced Search
 
 

Submitters